Research Papers:

Increased CCL19 expression is associated with progression in cervical cancer

Xiaoshu Zhang _, Yue Wang, Yanning Cao, Xueshan Zhang and Haiya Zhao

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:73817-73825. https://doi.org/10.18632/oncotarget.17982

Metrics: PDF 1684 views  |   HTML 2682 views  |   ?  


Xiaoshu Zhang1, Yue Wang1, Yanning Cao1, Xueshan Zhang1 and Haiya Zhao1

1Department of Immunology, Binzhou Medical University, Yantai, 264003, China

Correspondence to:

Xiaoshu Zhang, email: [email protected]

Keywords: cervical cancer, CCL19, EMT, invasion, proliferation

Received: December 20, 2016     Accepted: April 26, 2017     Published: May 18, 2017


Cervical cancer is the third most common cancer and the fourth leading cause of malignancy related mortality in women worldwide. CCL19 is highly expressed in human cancer cells, and ligand CCL19 binding to CCR7 induces actin polymerization and pseudopodia formation. However, whether or not CCL19 is involved in EMT of human cervical cancer needs further investigation. Using quantitative PCR and western blot analyses, we found that CCL19 is overexpressed in cervical cancer cell lines and tissues. Knockdown of CCL19 via siRNA inhibited the proliferation of cervical cancer cells by increasing apoptosis. Further analyses showed that inhibitory effects of CCL19 on cell migration and invasion were partly associated with EMT process. In conclusion, these data indicate that CCL19 is abnormally expressed in cervical cancer, indicating a novel and important role for CCL19 in cervical cancer malignant transformation.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17982